EP1086116A4 - Compositions destinees a l'administration pulmonaire d'acides nucleiques et procedes - Google Patents

Compositions destinees a l'administration pulmonaire d'acides nucleiques et procedes

Info

Publication number
EP1086116A4
EP1086116A4 EP99923263A EP99923263A EP1086116A4 EP 1086116 A4 EP1086116 A4 EP 1086116A4 EP 99923263 A EP99923263 A EP 99923263A EP 99923263 A EP99923263 A EP 99923263A EP 1086116 A4 EP1086116 A4 EP 1086116A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
pulmonary delivery
nucleic acids
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99923263A
Other languages
German (de)
English (en)
Other versions
EP1086116A1 (fr
Inventor
Clarence Frank Bennett
David J Ecker
Phillip Dan Cook
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of EP1086116A1 publication Critical patent/EP1086116A1/fr
Publication of EP1086116A4 publication Critical patent/EP1086116A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions destinées à l'administration pulmonaire d'acides nucléiques, en particulier d'oligonucléotides, et des procédés associés. Dans un mode de réalisation préféré, les compositions et les procédés de l'invention sont utilisés pour effectuer l'administration pulmonaire d'un oligonucléotide antisens chez un animal dans le but de moduler l'expression d'un gène chez cet animal à des fins thérapeutiques, prophylactiques ou de recherche.
EP99923263A 1998-05-21 1999-05-20 Compositions destinees a l'administration pulmonaire d'acides nucleiques et procedes Withdrawn EP1086116A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8358598A 1998-05-21 1998-05-21
US83585 1998-05-21
PCT/US1999/011214 WO1999060010A1 (fr) 1998-05-21 1999-05-20 Compositions destinees a l'administration pulmonaire d'acides nucleiques et procedes

Publications (2)

Publication Number Publication Date
EP1086116A1 EP1086116A1 (fr) 2001-03-28
EP1086116A4 true EP1086116A4 (fr) 2004-03-17

Family

ID=22179298

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99923263A Withdrawn EP1086116A4 (fr) 1998-05-21 1999-05-20 Compositions destinees a l'administration pulmonaire d'acides nucleiques et procedes

Country Status (3)

Country Link
EP (1) EP1086116A4 (fr)
AU (1) AU4007899A (fr)
WO (1) WO1999060010A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955443A (en) * 1998-03-19 1999-09-21 Isis Pharmaceuticals Inc. Antisense modulation of PECAM-1
US6197584B1 (en) * 1998-05-01 2001-03-06 Isis Pharmaceuticals, Inc. Antisense modulation of CD40 expression
US10745701B2 (en) 2007-06-28 2020-08-18 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
US20090324596A1 (en) 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
US8916531B2 (en) 2007-11-20 2014-12-23 Isis Pharmaceuticals, Inc. Modulation of CD40 expression

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019203A1 (fr) * 1992-03-16 1993-09-30 Isis Pharmaceuticals, Inc. Modulation par oligonucleotide de la proteine kinase c
WO1999011778A1 (fr) * 1997-09-02 1999-03-11 University Of Sheffield Traitement antisense de l'hypertension pulmonaire
WO2000020645A1 (fr) * 1998-10-05 2000-04-13 Isis Pharmaceuticals, Inc. Modulation de l'expression du facteur de necrose tumorale alpha (tnf-alpha) au moyen d'un oligonucleotide antisens
WO2000050050A1 (fr) * 1999-02-23 2000-08-31 Isis Pharmaceuticals, Inc. Formulation multiparticulaire

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591623A (en) * 1990-08-14 1997-01-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019203A1 (fr) * 1992-03-16 1993-09-30 Isis Pharmaceuticals, Inc. Modulation par oligonucleotide de la proteine kinase c
WO1999011778A1 (fr) * 1997-09-02 1999-03-11 University Of Sheffield Traitement antisense de l'hypertension pulmonaire
WO2000020645A1 (fr) * 1998-10-05 2000-04-13 Isis Pharmaceuticals, Inc. Modulation de l'expression du facteur de necrose tumorale alpha (tnf-alpha) au moyen d'un oligonucleotide antisens
WO2000050050A1 (fr) * 1999-02-23 2000-08-31 Isis Pharmaceuticals, Inc. Formulation multiparticulaire

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
LEVESQUE L. ET AL.: "Antisense oligonucleotides targeting human Protein Kinase C-alpha inhibit phorbol ester-induced reduction of Bradykinin-evoked Calcium mobilization in A549 cells", MOLECULAR PHARMACOLOGY, vol. 51, 1997, pages 209 - 216, XP002247729 *
MCKAY R.A. ET AL.: "Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human Protein Kinase C-alpha expression", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 3, 15 January 1999 (1999-01-15), pages 1715 - 1722, XP002247728 *
NICKLIN P.L. ET AL.: "Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): comparison with other delivery routes", PHARMACEUTICAL RESEARCH, vol. 15, no. 4, April 1998 (1998-04-01), pages 583 - 591, XP008019675 *
NYCE J.W. AND METZGER W.J.: "DNA antisense therapy for asthma in an animal model", NATURE, vol. 385, 20 February 1997 (1997-02-20), pages 721 - 725, XP000891493, ISSN: 0028-0836 *
PHAN S.H.: "New strategies for treatment of pulmonary fibrosis", THORAX, vol. 50, no. 4, 1 April 1995 (1995-04-01), pages 415 - 421, XP000601085, ISSN: 0040-6376 *
ROJANASAKUL Y. ET AL.: "Antisense inhibition of Silica-induced Tumor Necrosis Factor in alveolar macrophages", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 7, 14 February 1997 (1997-02-14), pages 3910 - 3914, XP002247730 *
See also references of WO9960010A1 *

Also Published As

Publication number Publication date
AU4007899A (en) 1999-12-06
WO1999060010A1 (fr) 1999-11-25
EP1086116A1 (fr) 2001-03-28

Similar Documents

Publication Publication Date Title
EP1248794A4 (fr) Modulation antisens de l'expression de la proteine smad7
FR2722506B1 (fr) Composition contenant des acides nucleiques, preparation et utilisations
EP1248791A4 (fr) Modulation anti-sens de l'expression de la caspase 3
DE69513998D1 (de) Verwendung von 2'-substituierten oligonukleotiden zur reduzierung der genexpression
WO2001048190A3 (fr) Utilisations therapeutiques d'oligonucleotides a lna modifie
EP1414842A4 (fr) Modulation antisens de l'expression d'acyl-coa cholesterol acyltransferase 2
EP1569695A4 (fr) Modulation antisens de l'expression d'apolipoproteine b
EP1165586A4 (fr) GENE TCL-1b ET PROTEINE, PROCEDES ET COMPOSITIONS S'Y RAPPORTANT
WO2003048324A3 (fr) Modulation antisens de l'expression de la phospholipide scramblase 3
EP2003207A3 (fr) Inhibition anti-sens d'expression PTP1B
WO2001080840A3 (fr) Agents cytotoxiques
EP1409509A4 (fr) Modulation antisens de l'expression de la proteine reactive c
EP1189918A4 (fr) Modulation antisens de l'expression d'integrine beta 3
EP1430072A4 (fr) Modulation antisens de l'expression de la proteine de transfert de l'ester de cholesteryle
WO2001032832A3 (fr) Modulation antisens de l'expression de la nucleoline
FR2790757B1 (fr) Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.
WO2004078941A3 (fr) Modulation de l'expression genetique au moyen d'hybrides adn/arn
WO2003054154A3 (fr) Modulation antisens de l'expression de la mucine 1, transmembranaire
TR199802648A3 (tr) Gen tedavisi için nüklein asit yapilari.
EP1131332A4 (fr) Modulation antisens de l'expression de la kappa b kinase beta inhibitrice
EP0979309A4 (fr) Oligonucleotides presentant une meilleure biodisponibilite
EP1086116A4 (fr) Compositions destinees a l'administration pulmonaire d'acides nucleiques et procedes
EP1250347A4 (fr) Modulation antisens de l'expression de akt-3
EP1248633A4 (fr) Modulation antisens de l'expression de glycogene synthase kinase 3 beta
HUP0402327A2 (hu) Inzulinszerű növekedési faktort kötő 5-ös fehérje expressziójának antiszensz módosítása

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20040202

17Q First examination report despatched

Effective date: 20050211

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ISIS PHARMACEUTICALS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060530